Abu-Jayyab A, Mahgoub A
Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Biosci Rep. 1987 Nov;7(11):839-42. doi: 10.1007/BF01119474.
The dopamine receptor agonist, bromocriptine, in a dose of 10 mg/kg i.p. for 14 days, in rats caused a significant increase in liver Na+/K+-ATPase activity, whereas sulpiride, a dopamine receptor antagonist, in a dose of 10 mg/kg, i.p. for 14 days, in rats, caused a significant decrease in liver Na+/K+-ATPase activity. Injection of bromocriptine and sulpiride simultaneously in a group of rats, under the same conditions and using the same doses caused a complete block of both stimulatory activity of bromocriptine and inhibitory activity of sulpiride on liver Na+/K+-ATPase activity. It is suggested that Na+/K+-ATPase may have a role in the action of dopaminergic-D2 receptors.
多巴胺受体激动剂溴隐亭，以10毫克/千克的腹腔注射剂量给药14天，可使大鼠肝脏钠钾ATP酶活性显著增加；而多巴胺受体拮抗剂舒必利，以10毫克/千克的腹腔注射剂量给药14天，可使大鼠肝脏钠钾ATP酶活性显著降低。在相同条件下，以相同剂量同时给一组大鼠注射溴隐亭和舒必利，可完全阻断溴隐亭的刺激活性和舒必利对肝脏钠钾ATP酶活性的抑制活性。提示钠钾ATP酶可能在多巴胺能D2受体的作用中发挥作用。
